CEBPA and leukemia: FTO was verified to be inhibited by R-2-hydroxyglutarate (R-2HG), thereby increasing m6A RNA modification in R-2HG-sensitive leukemia cells and decreasing the stability of MYC/CEBPA transcripts, which leads to the suppression of leukemia cell proliferation/viability and the inhibition of cell-cycle arrest and apoptosis (113).